Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 14;26(22):6862.
doi: 10.3390/molecules26226862.

Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease

Affiliations

Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease

William Hancock-Cerutti et al. Molecules. .

Abstract

High-density lipoprotein cholesterol (HDL-C) is thought to be atheroprotective yet some patients with elevated HDL-C levels develop cardiovascular disease, possibly due to the presence of dysfunctional HDL. We aimed to assess the metabolic fate of circulating HDL particles in patients with high HDL-C with and without coronary artery disease (CAD) using in vivo dual labeling of its cholesterol and protein moieties. We measured HDL apolipoprotein (apo) A-I, apoA-II, free cholesterol (FC), and cholesteryl ester (CE) kinetics using stable isotope-labeled tracers (D3-leucine and 13C2-acetate) as well as ex vivo cholesterol efflux to HDL in subjects with (n = 6) and without (n = 6) CAD that had HDL-C levels >90th percentile. Healthy controls with HDL-C within the normal range (n = 6) who underwent the same procedures were used as the reference. Subjects with high HDL-C with and without CAD had similar plasma lipid levels and similar apoA-I, apoA-II, HDL FC, and CE pool sizes with no significant differences in fractional clearance rates (FCRs) or production rates (PRs) of these components between groups. Subjects with high HDL-C with and without CAD also had similar basal and cAMP-stimulated ex vivo cholesterol efflux to HDL. When all subjects were considered (n = 18), unstimulated non-ABCA1-mediated efflux (but not ABCA1-specific efflux) was correlated positively with apoA-I production (r = 0.552, p = 0.017) and HDL FC and CE pool sizes, and negatively with the fractional clearance rate of FC (r = -0.759, p = 4.1 × 10-4) and CE (r = -0.652, p = 4.57 × 10-3). Our data are consistent with the concept that ex vivo non-ABCA1 efflux capacity may correlate with slower in vivo turnover of HDL cholesterol moieties. The use of a dual labeling protocol provided for the first time the opportunity to assess the association of ex vivo cholesterol efflux capacity with in vivo HDL cholesterol metabolic parameters.

Keywords: cholesterol efflux; coronary artery disease; hyperalphalipoprotenemia; lipoprotein metabolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pool size (PS), production rate (PR), and fractional catabolic rate (FCR) of HDL apoA-I, apoA-II, free cholesterol (FC), and cholesteryl ester (CE). Data are shown as the mean. Error bars represent the standard deviation. n = 6 for each group. Differences among groups were determined using ANOVA followed by a Tukey-HSD post-hoc test for variables with a normal distribution and the Kruskal–Wallis test followed by a post-hoc Dunn’s test for variables with a non-normal distribution.

References

    1. Gordon D.J., Rifkind B.M. High-density lipoprotein--the clinical implications of recent studies. N. Engl. J. Med. 1989;321:1311–1316. doi: 10.1056/NEJM198911093211907. - DOI - PubMed
    1. Goldbourt U., Yaari S., Medalie J.H. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler. Thromb. Vasc. Biol. 1997;17:107–113. doi: 10.1161/01.ATV.17.1.107. - DOI - PubMed
    1. Emerging Risk Factors C., Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., Thompson A., Wood A.M., Lewington S., Sattar N., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000. doi: 10.1001/jama.2009.1619. - DOI - PMC - PubMed
    1. Genest J., Jr., Bard J.M., Fruchart J.C., Ordovas J.M., Schaefer E.J. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler. Thromb. 1993;13:1728–1737. doi: 10.1161/01.ATV.13.12.1728. - DOI - PubMed
    1. Casula M., Colpani O., Xie S., Catapano A.L., Baragetti A. HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. Cells. 2021;10:1869. doi: 10.3390/cells10081869. - DOI - PMC - PubMed